In conclusion, our analysis suggests that MYC and/or BCL2 protein overexpression, and particularly co-overexpression can be readily used to identify patients who have an unsatisfactory prognosis in DLBCL when treated with R-CHOP, and MYC and BCL2 could be candidates for novel therapeutic targets. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.